Skip to content

瑟利贝尔

US · CBLL #3313 按市值排名 上市于 2024
25.04 -2.60 -9.41%
实时 - 追踪5344个代码 - 心跳于351秒前 · 2026-10-16 19:39

估值 各估值倍数与自身5年区间的对比

市净率 7.02 高于历史水平 第93百分位
5年平均 2.22 · 在Medical Devices中排名第101/125
市盈率 -13.34 处于历史正常水平 第56百分位
5年平均 -15.42 · 前瞻 -12.79
市销率 8.84 处于历史正常水平 第51百分位
5年平均 9.47 · 前瞻 6.89 · 在Medical Devices中排名第111/136

同业对比 Medical Devices

公司 市值 市盈率(TTM) 市净率 股息率
瑟利贝尔 (CBLL) 960.99M -14.23 7.49 0.00%
Abbott Laboratories (ABT) 181.50B 33.94 3.55 2.33%
Medtronic (MDT) 121.20B 23.34 2.41 3.01%
Stryker Corp (SYK) 113.02B 30.53 4.71 1.18%
Boston Scientific (BSX) 64.33B 17.97 2.58 0.00%
Edwards Lifesciences (EW) 49.92B 50.35 4.70 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值33.86 经济护城河None 不确定性Very High

当前股价低于晨星合理价值估算35.2%。

合理价值

CeriBell Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 31% discount to our quantitative fair value estimate of $33.86 per share; however, caution is warranted due to this estimate's very high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 7.0 ranks in the bottom 50% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.

The company's balance sheet is an additional encouraging factor. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 9.2, a core component of leverage, lies in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

经济护城河

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:39:41 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

瑟利贝尔 讨论区 0 条评论

发表评论